JP5770711B2 - 細胞中への免疫原性分子のデリバリーに適したＣｙａＡポリペプチド突然変異体及びポリペプチド誘導体 - Google Patents

細胞中への免疫原性分子のデリバリーに適したＣｙａＡポリペプチド突然変異体及びポリペプチド誘導体 Download PDF

Info

Publication number
JP5770711B2
JP5770711B2 JP2012501286A JP2012501286A JP5770711B2 JP 5770711 B2 JP5770711 B2 JP 5770711B2 JP 2012501286 A JP2012501286 A JP 2012501286A JP 2012501286 A JP2012501286 A JP 2012501286A JP 5770711 B2 JP5770711 B2 JP 5770711B2
Authority
JP
Japan
Prior art keywords
cyaa
bordetella
polypeptide
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012501286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521207A5 (enExample
JP2012521207A (ja
Inventor
セボ ペーター
セボ ペーター
オシコバ アドリアナ
オシコバ アドリアナ
マシン ジリ
マシン ジリ
ファヨル カトリーヌ
ファヨル カトリーヌ
クルセク ジャン
クルセク ジャン
バスラー マレク
バスラー マレク
レクレル クロード
レクレル クロード
オジッカ ラディム
オジッカ ラディム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09155929.4A external-priority patent/EP2233569B1/en
Priority claimed from US12/409,324 external-priority patent/US8017132B2/en
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of JP2012521207A publication Critical patent/JP2012521207A/ja
Publication of JP2012521207A5 publication Critical patent/JP2012521207A5/ja
Application granted granted Critical
Publication of JP5770711B2 publication Critical patent/JP5770711B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012501286A 2009-03-23 2010-03-23 細胞中への免疫原性分子のデリバリーに適したＣｙａＡポリペプチド突然変異体及びポリペプチド誘導体 Expired - Fee Related JP5770711B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09155929.4A EP2233569B1 (en) 2009-03-23 2009-03-23 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
EP09155929.4 2009-03-23
US12/409,324 2009-03-23
US12/409,324 US8017132B2 (en) 2009-03-23 2009-03-23 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
PCT/EP2010/053795 WO2010136231A1 (en) 2009-03-23 2010-03-23 MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL

Publications (3)

Publication Number Publication Date
JP2012521207A JP2012521207A (ja) 2012-09-13
JP2012521207A5 JP2012521207A5 (enExample) 2013-05-09
JP5770711B2 true JP5770711B2 (ja) 2015-08-26

Family

ID=42224889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012501286A Expired - Fee Related JP5770711B2 (ja) 2009-03-23 2010-03-23 細胞中への免疫原性分子のデリバリーに適したＣｙａＡポリペプチド突然変異体及びポリペプチド誘導体

Country Status (7)

Country Link
EP (1) EP2411513B1 (enExample)
JP (1) JP5770711B2 (enExample)
CN (2) CN102439146A (enExample)
CA (1) CA2755694A1 (enExample)
ES (1) ES2612945T3 (enExample)
RU (1) RU2585216C2 (enExample)
WO (1) WO2010136231A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2975120A1 (en) 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
WO2018091613A1 (en) * 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3323426A1 (en) * 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3381931A1 (en) * 2017-03-29 2018-10-03 Mikrobiologicky ustav AV CR, v.v.i. Adenylate cyclase toxoid with reduced cytolytic activity
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
FR2638169B1 (fr) * 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
PT637335E (pt) 1992-04-21 2007-10-31 Pasteur Institut Mutantes recombinantes para induzir respostas imunitárias específicas
FR2805544B1 (fr) * 2000-02-28 2004-07-16 Pasteur Institut Adenylcyclase recombinante et procede de tri de molecules a activite proteolytique utilisant cette adenylcyclase
ATE438409T1 (de) * 2000-09-15 2009-08-15 Pasteur Institut Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
WO2005035557A2 (en) * 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
ES2293178T3 (es) * 2004-03-18 2008-03-16 Institut Pasteur Proteina recombinante que contiene epitopos del papilomavirus humano insertados en un proteina adenilato ciclasa o un fragmento de la misma y usos terapeuticos de la misma.

Also Published As

Publication number Publication date
EP2411513A1 (en) 2012-02-01
RU2011138706A (ru) 2013-04-27
WO2010136231A1 (en) 2010-12-02
CN102439146A (zh) 2012-05-02
JP2012521207A (ja) 2012-09-13
ES2612945T3 (es) 2017-05-19
CN105602924A (zh) 2016-05-25
RU2585216C2 (ru) 2016-05-27
CA2755694A1 (en) 2010-12-02
EP2411513B1 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
US9957301B2 (en) Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response
JP5770711B2 (ja) 細胞中への免疫原性分子のデリバリーに適したＣｙａＡポリペプチド突然変異体及びポリペプチド誘導体
AU2015233542B2 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
US9708596B2 (en) Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
US11759508B2 (en) Antigenic peptides for treatment of B-cell malignancy
US20150352200A1 (en) Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
KR20230142704A (ko) 암 면역요법을 위한 조직 특이적 항원
US8017132B2 (en) Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
US20250092143A1 (en) Genetically engineered multifunctional exosomes for immunotherapy
Howland Yeast-based vaccine approaches to cancer immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150625

R150 Certificate of patent or registration of utility model

Ref document number: 5770711

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees